New discoveries in the basic science understanding of Peyronie’s disease

Current Urology Reports

Volumn 5, Issue 6, 2004, Pages 478-484

  Jalkut, Mark ^b   Gonzalez Cadavid, Nestor ^b   Rajfer, Jacob ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

Early Growth Response Protein; Erect Penis; Erectile Dysfunction; Tunica Albuginea; Wogonin

Indexed keywords

ANIMAL; HUMAN; MALE; PATHOLOGY; PATHOPHYSIOLOGY; PENIS; PEYRONIE DISEASE; REVIEW;

ANIMALS; HUMANS; MALE; PENILE INDURATION; PENIS;

EID: 16644364334     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0074-y     Document Type: Article

References (51)

1. de La Peyronie F: Sur Quelsques obstacles qui s’opposent a l’ejaculation naturelle de la semance. Med Aca R Chir 1743, 1:425.
2. Lindsay MB, Schain DM, Grambsch P, et al.: The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991, 146:1007–1009.
3. Schwarzer U, Sommer F, Klotz T, et al.: The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001, 88:727–730. DOI: 10.1046/j.1464-4096.2001.02436.x
4. Mulhall JP, Creech SD, Boorjian SA, et al.: Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004, 171:2350–2353. DOI: 10.1097/01.ju.0000127744.18878.f1
5. Kadioglu A, Oktar T, Kandirali E, et al.: Incidentally diagnosed Peyronie’s disease in men presenting with erectile dysfunction. Int J Impot Res 2004 [Epub head of print].
6. Williams JL, Thomas GG: The natural history of Peyronie’s disease. J Urol 1970, 103:75–76.
7. Gelbard MK, Dorey F, James K: The natural history of Peyronie’s disease. J Urol 1990, 144:1376–1379.
8. Smith BH: Peyronie’s disease. Am J Clin Pathol 1966, 45:670–678.
9. Somers KD, Dawson DM: Fibrin deposition in Peyronie’s disease plaque. J Urol 1997, 157:311–315. DOI: 10.1016/S0022-5347(01)65367-9
10. Furey CA: Peyronie’s disease: a treatment by the local injection of meticortelone and hydrocortisone. J Urol 1957, 55:251–266.
11. Jarow JP, Lowe FC: Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997, 158:1388–1390. DOI: 10.1016/S0022-5347(01)64222-8
12. Devine CJ Jr, Somers KD, Jordan SG, Schlossberg SM: Proposal: trauma as the cause of the Peyronie’s lesion. J Urol 1997, 157:285–290. DOI: 10.1016/S0022-5347(01)65361-8
13. Brock G, Hsu GL, Nunes L, et al.: The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997, 157:276–281. DOI: 10.1016/S0022-5347(01)65359-X
14. Bystrom J, Rubio C: Induratio penis plastica Peyronie’s disease: clinical features and etiology. Scand J Urol Nephrol 1976, 10:12–20.
15. Ling RS: The genetic factor in Dupuytren’s disease. J Bone Joint Surg 1963, 45:709–718.
16. Chilton CP, Castle WM, Westwood CA, Pryor JP: Factors associated in the aetiology of Peyronie’s disease. Br J Urol 1982, 54:748–750.
17. Nyberg LM Jr, Bias WB, Hochberg MC, Walsh PC: Identification of an inherited form of Peyronie’s disease with autosomal dominant inheritance and association with Dupuytren’s contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982, 128:48–51.
18. Willscher MK, Cwazka WF, Novicki DE: The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie’s disease. J Urol 1979, 122:34–35.
19. Ziegelbaum M, Thomas A Jr, Zachary AA: The association of Peyronie’s disease with HLA B7 cross-reactive antigens: a case report of identical twins. Cleve Clin J Med 1987, 54:427–430.
20. Rompel R, Mueller-Eckhardt G, Schroeder-Printzen I, Weidner W: HLA antigens in Peyronie’s disease. Urol Int 1994, 52:34–37. DOI: 10.1159/000282566
21. Rompel R, Weidner W, Mueller-Eckhardt G: HLA association of idiopathic Peyronie’s disease: an indication of autoimmune phenomena in etiopathogenesis? Tissue Antigens 1991, 38:104–106.
22. Hauck EW, Hauptmann A, Weidner W, et al.: Prospective analysis of HLA classes I and II antigen frequency in patients with Peyronie’s disease. J Urol 2003, 170:1443–1446. DOI: 10.1097/01.ju.0000076488.89748.e1
23. Schiavino D, Sasso F, Nucera E, et al.: Immunologic findings in Peyronie’s disease: a controlled study. Urology 1997, 50:764–768. DOI: 10.1016/S0090-4295(97)00333-6
24. Ralph DJ, Schwartz G, Moore W, et al.: The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997, 157:291–294. DOI: 10.1016/S0022-5347(01)65362-X
25. Hauck EW, Domann E, Hauptmann A, et al.: Prospective analysis of 16S rDNA as a highly sensitive marker for bacterial presence in Peyronie’s disease plaques. J Urol 2003, 170:2053–2056. DOI: 10.1097/01.ju.0000080297.86237.ee
26. El-Sakka AI, Hassoba HM, Pillarisetty RJ, et al.: Peyronie’s disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391–1394. DOI: 10.1016/S0022-5347(01)64223-X
27. Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90:1–7. DOI: 10.1172/JCI115821
28. Shah M, Foreman DM, Ferguson MW: Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 1992, 339:213–214. DOI: 10.1016/0140-6736(92)90009-R
29. El-Sakka AI, Selph CA, Yen TS, et al.: The effect of surgical trauma on rat tunica albuginea. J Urol 1998, 159:1700–1707. DOI: 10.1097/00005392-199805000-00097
30. El-Sakka AI, Hassoba HM, Chui RM, et al.: An animal model of Peyronie’s-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284–2290. DOI: 10.1016/S0022-5347(01)68236-3
31. Bivalacqua TJ, Diner EK, Novak TE, et al.: A rat model of Peyronie’s disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000, 163:1992–1998. DOI: 10.1016/S0022-5347(05)67616-1
32. Bivalacqua TJ, Champion HC, Leungwattanakij S, et al.: Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie’s-like condition in the rat. J Androl 2001, 22:497–506.
33. Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF: Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie’s disease. BJU Int 2003, 91:830–838. DOI: 10.1046/j.1464-410X.2003.04224.x
34. Chung SI, Lee SY, Uchino R, Carmassi F: Factors that control extravascular fibrinolysis. Semin Thromb Hemost 1996, 22:479–488. DOI: 10.1055/s-2007-999048
35. Lue TF: Peyronie’s disease: an anatomically based hypothesis and beyond. Int J Impot Res 2002, 14:411–413. DOI: 10.1038/sj.ijir.3900876
36. Lin CS, Lin G, Wang Z, et al.: Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie’s disease. Biochem Biophys Res Commun 2002, 295:1014–1019. DOI: 10.1016/S0006-291X(02)00765-9
37. Wang Z, Lin G, Lue TF, Lin CS: Wogonin suppresses cellular proliferation and expression of monocyte chemoattractant protein 1 in Peyronie’s plaque-derived cells. BJU Int 2003, 92:753–757. DOI: 10.1046/j.1464-410X.2003.04464.x
38. Gentile V, Modesti A, La Pera G, et al.: Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie’s disease and veno-occlusive dysfunction. J Androl 1996, 17:96–103.
39. Wahl SM: Inflammation and growth factors. J Urol 1997, 157:303–305. DOI: 10.1016/S0022-5347(01)65365-5
40. Somers KD, Dawson DM, Wright GL Jr, et al.: Cell culture of Peyronie’s disease plaque and normal penile tissue. J Urol 1982, 127:585–588.
41. Somers KD, Winters BA, Dawson DM, et al.: Chromosome abnormalities in Peyronie’s disease. J Urol 1987, 137:672–675.
42. Mulhall JP, Nicholson B, Pierpaoli S, et al.: Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie’s disease. Int J Impot Res 2004, 16:288–293. DOI: 10.1038/sj.ijir.3901170
43. Perinchery G, El-Sakka AI, Angan A, et al.: Microsatellite alterations and loss of heterozygosity in Peyronie’s disease. J Urol 2000, 164:842–846. DOI: 10.1016/S0022-5347(05)67324-7
44. Ferrini MG, Vernet D, Magee TR, et al.: Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 2002, 6:283–294. DOI: 10.1006/niox.2001.0421
45. Vernet D, Ferrini MG, Valente EG, et al.: Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide 2002, 7:262–276. DOI: 10.1016/S1089-8603(02)00124-6
46. Mulhall JP: Expanding the paradigm for plaque development in Peyronie’s disease. Int J Impot Res 2003, 15(suppl 5):S93-S102. Critical study. DOI: 10.1038/sj.ijir.3901082
47. Valente EG, Vernet D, Ferrini MG, et al.: L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229–244. DOI: 10.1016/j.niox.2003.12.002
48. Davila HH, Magee TR, Vernet D, et al.: Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibriotic plaque in an animal model of Peyronie’s disease. Biol Reprod 2004, 71:1568–1577. DOI: 10.1095/biolreprod.104.030833
49. Magee TR, Qian A, Rajfer J, et al.: Gene expression profiles in the Peyronie’s disease plaque. Urology 2002, 59:451–457. DOI: 10.1016/S0090-4295(01)01578-3
50. Kolb M, Margetts PJ, Galt T, et al.: Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001, 163:770–777.
51. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF: Comparison of gene expression profiles between Peyronie’s disease and Dupuytren’s contracture. Urology 2004, 64:399–404. Interesting study. DOI: 10.1016/j.urology.2004.04.006